Skip to main content

Recent News

#ACR Best 2024 - Day 4

Although the last day of ACR Convergence 2024 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today.  As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.

Read Article
Apremilast Benefits and Risks in PsA Dr. Akhil Sood discusses abstracts 1466, 2583, 0598 and 2640 discussing the use of apremilast in PsA, presented at #ACR24. https://t.co/SSEeR9Xt9B https://t.co/cUeSUQoRsO
Dr. John Cush @RheumNow (  View Tweet)
#ACR24 BEST Abstracts from Day 2 Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty. https://t.co/9qiPhemEPl https://t.co/uGQEiCcfah
Dr. John Cush @RheumNow (  View Tweet)
#ACR24 - Day 2 Report Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024. https://t.co/TEWW0mDyl8 https://t.co/mZuqayonPN
Dr. John Cush @RheumNow (  View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.

Dr. John Cush @RheumNow (  View Tweet)

Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA For years, rheumatologists have championed weight loss as a cornerstone of care for patients with rheumatoid arthritis (RA) and obesity. RA is an independent risk factor for cardiovascular disease (CVD), a… https://t.co/iozo0FQFzj https://t.co/93e4nZMHJo
Dr. John Cush @RheumNow (  View Tweet)
RheumNow Day 2 Recap: #ACR24 Highlights Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush @RheumNow (  View Tweet)

RA: One JAK to Rule Them All? Dr. Brian Jaros reports on abstract 1362, presented at #ACR24. https://t.co/QChMyma3Y2 https://t.co/qq3BqpT2Gh

Dr. John Cush @RheumNow (  View Tweet)
Transplant-free Survival Predictors in Idiopathic Inflammatory Myopathies-ILD Dr. Gaby Martinez discusses abstract 0333, Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease, presented at #ACR24.… https://t.co/3TSZ6PvZsD https://t.co/DLdzzfXhhp
Dr. John Cush @RheumNow (  View Tweet)
Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis Dr. Antoni Chan interviews Dr. Catherine Bakewell on the Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis, at #ACR24. https://t.co/iCwNsuo7xz @synovialjoints https://t.co/Tjx3CE27TK
Dr. John Cush @RheumNow (  View Tweet)
PsA Potpourri Dr. Arthur Kavanaugh reviewed highlights on adult and pediatric sessions on uveitis, as well as interesting abstracts, at #ACR24 https://t.co/jsCMKHBFMk https://t.co/roZOZT3Mqd
Dr. John Cush @RheumNow (  View Tweet)

JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P

Dr. John Cush @RheumNow (  View Tweet)

Where there’s smoke, there’s flare: how pollution fuels RA The World Health Organisation (WHO) has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 (1, 2)… https://t.co/hmXPa492Qr https://t.co/BBClCplk8Z

Dr. John Cush @RheumNow (  View Tweet)
Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq
Dr. John Cush @RheumNow (  View Tweet)
Health Literacy: the forgotten social determinant of health? Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/15gvQxZHNN https://t.co/VqCjZY4tYI
Dr. John Cush @RheumNow (  View Tweet)

Methotrexate to Prevent RA, Clear as Mud

Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk ACPA- patients.

Read Article
ICYMI: Precision medicine in Ssc ILD? Yes! -Watch and wait approach can cause irreversible lung damage. -⬆️CRP: biomarker of response (predicts mortality) -⬆️KL-6: biomarker of severity (predicts progression of fibrosis) -FAPI-PET: can eval disease activity vs response to ttx.… https://t.co/bTepwrsuNN https://t.co/e6xjtuquka
Adela Castro @AdelaCastro222 (  View Tweet)
Beyond the Needle: Redefining the Assessment of Lupus Nephritis Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE). https://t.co/fvGG0BZbOL #ACR24 https://t.co/wPXQz9Vese
Dr. John Cush @RheumNow (  View Tweet)
Cancer Survival in RA Dr. Eric Dein interviews Joshua Hsieh about abstract 0474, Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis, presented at #ACR24. https://t.co/2957Nq6Ajy https://t.co/3swVyigA3g
Dr. John Cush @RheumNow (  View Tweet)
COVID Associated Immune Disease Dr. Len Calabrese reports on a session he participated in discussing if Covid-19 is associated or causal for autoimmune disease. Reporting from #ACR24 https://t.co/vFdlf9XVzf https://t.co/JhpglNVIt7
Dr. John Cush @RheumNow (  View Tweet)